Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30214735 | 0.85 | ALDH1A1 (0.43) | TRPV4EPHX2MEN1ALDH1A1TSHR | |
| SCHEMBL310121 | 0.85 | ALDH1A1 (0.43) | TRPV4EPHX2MEN1ALDH1A1TSHR | |
| SCHEMBL2183059 | 0.83 | KIF11 (0.47) | EPHX2KMT2AKIF11CA1CA2 | |
| SCHEMBL2748213 | 0.83 | CA1 (0.40) | TRPV4MEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL14684308 | 0.83 | ADRA1A (0.43) | EPHX2MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL30918492 | 0.83 | KIF11 (0.47) | EPHX2KMT2AKIF11CA1CA2 | |
| SCHEMBL11772105 | 0.80 | KIF11 (0.41) | TRPV4EPHX2MEN1ALDH1A1TSHR | |
| SCHEMBL15745423 | 0.80 | ALDH1A1 (0.40) | TRPV4EPHX2MEN1ALDH1A1TSHR | |
| SCHEMBL25362679 | 0.79 | MCL1 (0.51) | TRPV4MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL66378 | 0.79 | TRPV4 (0.53) | TRPV4MEN1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-3555078-B1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-14 | — | — | US | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20200071310-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20200062781-A1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-02-27 | — | — | US | disclosed |
| US-20200031820-A1 | 3-CARBOXYLIC ACID PYRROLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-01-30 | — | — | US | disclosed |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-3555088-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2009045382-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009017719-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008076752-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| EP-1664010-A1 | SULFONAMIDES ANTAGONISING N-TYPE CALCIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005068448-A1 | SULFONAMIDES ANTAGONISING N-TYPE CALCIUM CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-07-28 | — | — | WO | disclosed |
| US-3995042-A | MUSCLE RELAXANTS, CENTRAL NERVOUS SYSTEM STIMULANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-11-30 | — | — | US | disclosed |
| US-3957799-A | STIMULANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-05-18 | — | — | US | disclosed |
| US-3946025-A | MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078216-B2 | Bisaryl amides as NRF2 activators | NFE2L2, KEAP1, NQO1 | TRPV4 3449/4885EPHX2 973/4885MEN1 4698/4885 |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | TRPV4 3449/4885EPHX2 973/4885MEN1 4698/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | TRPV4 4643/4885EPHX2 2121/4885MEN1 1351/4885 |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | TRPV1, TRPV2, TRPA1 | TRPV4 6/4885EPHX2 2028/4885MEN1 4627/4885 |
| US-20200031820-A1 | 3-CARBOXYLIC ACID PYRROLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NFE2 | TRPV4 3414/4885EPHX2 1053/4885MEN1 4789/4885 |
| US-20200062781-A1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | TRPV4 3487/4885EPHX2 609/4885MEN1 4383/4885 |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | NFE2L2, KEAP1, NQO1 | TRPV4 3487/4885EPHX2 609/4885MEN1 4383/4885 |
| US-20200071310-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, NQO1, KEAP1 | TRPV4 2804/4885EPHX2 1168/4885MEN1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.